US Rabies Trial Yields Positive Results

The preliminary results of the first Phase II clinical trial of investigational rabies monoclonal antibody combination are positive, according to Dutch biopharma company Crucell.

The U.S. trial was set up as a single-blind, controlled study in 140 healthy volunteers to test the antibody in association with Sanofi Pasteur human diploid cell rabies vaccine. The subjects were randomized into the study — 80 in the CL184 monoclonal antibody combination treatment group, 40 in the human rabies immune globulin group and 20 in the placebo group.

All subjects completed the study, only mild-to-moderate adverse events were reported and the overall systemic safety was comparable with that of the placebo. The neutralizing activity against the rabies virus was comparable with that of standard care.